Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis
Background This study was designed to investigate whether COVID-19 patients with recently received immunotherapy or other anti-cancer treatments had more severe symptoms and higher mortality. Methods A literature search was performed using the electronic platforms to obtain relevant research studies...
Main Authors: | Bolin Wang, Yan Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1824646 |
Similar Items
-
Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience
by: Christopher C. T. Sng, et al.
Published: (2020-11-01) -
The Impact of COVID-19 on Cancer
by: Li Y, et al.
Published: (2021-09-01) -
COVID-19 in cancer patients: risk, clinical features, and management
by: Cuiwei Liu, et al.
Published: (2020-08-01) -
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
by: Silvia Vivarelli, et al.
Published: (2020-08-01) -
Immunological alternation in COVID-19 patients with cancer and its implications on mortality
by: Guangyao Cai, et al.
Published: (2021-01-01)